In ovarian cancer, moderate overexpression of LSD1, particularly in stage IIIC and high-grade tumors, is linked to aggressive tumor signatures, including upregulated cell cycle genes and downregulated immune response genes, which correlate with poorer survival in some cohorts [186]. This evidence concerns the gene KDM1A and ovarian cancer.